Treating Menière’s disease with rimegepant
A recent hypothesis states that Menière’s disease is caused by inappropriate expression, i.e. enhanced release of the neurotransmitter calcitonin gene-related peptide. Here, we tested this hypothesis by administering rimegepant, a new calcitonin gene-related peptide antagonist approved for the acut...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2025-02-01
|
| Edice: | Swiss Medical Weekly |
| On-line přístup: | https://smw.ch/index.php/smw/article/view/4147 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|